Signaling pathways involved in the cardioprotective effects of cannabinoids.

  title={Signaling pathways involved in the cardioprotective effects of cannabinoids.},
  author={Philippe L{\'e}picier and Annie Bibeau-Poirier and Caroline Lagneux and Marc J. Servant and Daniel Lamontagne},
  journal={Journal of pharmacological sciences},
  volume={102 2},
The aim of the present article is to review the cardioprotective properties of cannabinoids, with an emphasis on the signaling pathways involved. Cannabinoids have been reported to protect against ischemia in rat isolated hearts, as well as in rats and mice in vivo. Although these effects have been observed mostly with a pre-treatment of a cannabinoid, we report that the selective CB(2)-receptor agonist JWH133 is able to reduce infarct size when administered either before ischemia, during the… 

Figures from this paper

Studies investigating the mechanisms of the cardioprotective effects of cannabidiol

The characterisation of the pharmacology of CBD in vivo showed that; firstly, CB1 receptor activation causes a hypotensive response which can be dose-dependently inhibited by AM251; secondly, both CBD and AM251 alone can induce vasodepressor responses and finally, CBD can potentiate the AM251-mediated hypotension when co-administered, suggesting possible cross-talk between the CB1 and GPR55.

Activation of Cannabinoid Type 2 Receptor by JWH133 Protects Heart Against Ischemia/Reperfusion-Induced Apoptosis

It is demonstrated that activation of CB2 receptor by JWH133 prevent apoptosis during ischemia/reperfusion through inhibition of the intrinsic mitochondria-mediated apoptotic pathway and involvement of the PI3K/Akt signal pathway.


The endocannabinoid system (ECS) appears to play a limited role in cardiovascular regulation under normal physiological conditions, but in various disease conditions, the ECS may become overactivated and play important protective and/or detrimental roles.

Regulatory Role of Cannabinoid Receptor 1 in Stress-Induced Excitotoxicity and Neuroinflammation

Corresponding animal experiments indicated that a lack of CB1 produces hypothalamic/pituitary/adrenal (HPA) axis dysregulation and exacerbates stress-induced excitotoxic/neuroinflammatory responses, and multifaceted neuroprotective effects suggest that CB1 activation could be a new therapeutic strategy against neurological-neuropsychiatric pathologies with HPA axis Dysregulation and an excitOToxic/NEuroinflammatory component in their pathophysiology.

Ligand Activation of Cannabinoid Receptors Attenuates Hypertrophy of Neonatal Rat Cardiomyocytes

In conclusion, CB-13 inhibits cardiomyocyte hypertrophy through AMPK-eNOS signaling and may represent a novel therapeutic approach to cardioprotection.

Endogenous cannabinoid system regulates intestinal barrier function in vivo through cannabinoid type 1 receptor activation.

  • S. ZoppiJ. Madrigal J. Leza
  • Biology, Medicine
    American journal of physiology. Gastrointestinal and liver physiology
  • 2012
CB1R exerts a protective role in the colon in vivo through the regulation of intestinal secretion of IgA and paracellular permeability and Pharmacological modulation of cannabinoid system within the gastrointestinal tract might be therapeutically useful in conditions on which intestinal inflammation and barrier dysfunction takes place after exposure to stress.

Endocannabinoids and cannabinoid receptors in ischaemia–reperfusion injury and preconditioning

The evidence supporting the therapeutic utility of selective CB2 receptor agonists, which are devoid of psychoactive effects, are delineated, as a promising new approach to limit I/R‐induced tissue damage.

The preventive effect of cannabinoids on reperfusion-induced ischemia of mouse kidney.

Pharmacological Properties, Therapeutic Potential and Molecular Mechanisms of JWH133, a CB2 Receptor-Selective Agonist

Based on the available data, this review proposes the possibilities of developing JWH133 as a promising therapeutic agent; however, further safety and toxicity studies in preclinical studies and clinical trials in humans are warranted.

Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations.

In the absence of a cellular storage mechanism for endocannabinoids, their tissue levels are determined by the balance between the rate of their “on-demand” synthesis and their enzymatic degradation.



Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide

The results suggest an involvement of endocannabinoids, acting through the CB2 receptors, in the cardioprotection triggered by LPS against myocardial ischaemia, which could be attributed to a relationship between cannabinoids and NO.

The endogenous cardiac cannabinoid system: a new protective mechanism against myocardial ischemia.

The ability of cannabinoids to reduce infarct size has been confirmed in vivo in anesthetized mice and rats and appears to be mediated through CB2-receptors, an important mechanism of protection against myocardial ischemia.

Essential activation of PKC-delta in opioid-initiated cardioprotection.

The results suggest that PKC-delta is a key second messenger in the cardioprotective effects of delta(1)-opioid receptor stimulation in rats, and rottlerin abolished opioid-inducedCardioprotection.

Cannabinoids and neuroprotection

The experimental evidence supporting different ways by which cannabinoids may act as neuroprotective agents is presented and discussed with regard to both preclinical and clinical studies in disease states such as cerebral ischemia, brain trauma, and Multiple Sclerosis.

Stress-activated protein kinase phosphorylation during cardioprotection in the ischemic myocardium.

The data suggest that SB-203580 likely attenuates IPC via the inhibition of kinases other than p38, which may include JNK, and suggest that activation of JNK during early reperfusion may be an important component of cardioprotection.

Endocannabinoids protect the rat isolated heart against ischaemia

Endocannabinoids exert a strong cardioprotective effect in a rat model of ischaemia–reperfusion that is mediated mainly through CB2‐receptors, and involves p38, ERK1/2, as well as PKC activation.

Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia‐reperfusion injury: involvement of cytokine/chemokines and PMN

It is demonstrated for the first time that exogenous and endogenous CB2‐R activation reduces the leukocyte‐dependent myocardial damage associated with an I/R procedure.

Differential activation of extracellular signal regulated kinase isoforms in preconditioning and opioid-induced cardioprotection.

A key role is suggested for the 44-kDa isoform of ERK in the cytoplasm during cardioprotection induced by either IPC or stimulation of the delta(1)-opioid receptor.